Draft:Paul Dalby
Submission declined on 9 May 2024 by Paul W (talk). This submission's references do not show that the subject qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published, reliable, secondary sources that are independent of the subject (see the guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see technical help and learn about mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia. This submission is not adequately supported by reliable sources. Reliable sources are required so that information can be verified. If you need help with referencing, please see Referencing for beginners and Citing sources.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|
- Comment: No references to significant (ie more than routine reporting or passing mentions) in reliable, independent, secondary sources with reputations for accuracy and fact-checking. Two sections completely unsupported by inline citations. Paul W (talk) 11:36, 9 May 2024 (UTC)
Paul Dalby (born 8 August 1973) is a British chemist and biochemist. He is a professor of Biochemical Engineering and Biotechnology.[1] and co-director of the Future Targeted Healthcare Manufacturing Hub[2] at University College London, where he is also Deputy Head of the Department of Biochemical Engineering.[3]
Early life and education
[edit]Dalby was born on 8 August 1973 in Northampton, UK.[citation needed] He attended Sponne School (1984–1991),[citation needed] and read Natural Sciences at Gonville and Caius College, University of Cambridge from 1991.[citation needed] Dalby was awarded a Master of Arts degree in Natural Sciences from the University of Cambridge in 1994, and carried out undergraduate research with Prof. D. H. Williams (chemistry).[citation needed] He obtained his PhD in protein folding and engineering from the University of Cambridge in 1998 under the supervision of Sir Alan Fersht at the MRC Centre for Protein Engineering.[citation needed]
Career
[edit]Dalby undertook post-doctoral research with Prof William DeGrado at the University of Pennsylvania (1998–2000), before accepting a Lectureship in Biochemical Engineering at University College London in 2000.[citation needed]
In 2013, Dalby was appointed Professor of Biochemical Engineering and Biotechnology at University College London, where he continues to work.[citation needed]
Dalby was Director of the EPSRC Centre for Doctoral Training in Innovative Manufacturing in Emergent Macromolecular Therapies (2012-2022), Co-Director of the EPSRC Centre for Innovative Manufacturing in Emergent Macromolecular Therapies (2011-2016), and Co-Director of the EPSRC Future Targeted Healthcare Manufacturing Hub (2016-2024).[2] From 2008 to 2023 Dalby was Chair of the Royal Society of Chemistry Biotechnology Group.[citation needed]
Research
[edit]Dalby applies chemical, biophysical and process engineering methods and principles to understand the properties of proteins, and then engineer or formulate them for use as therapeutics, vaccines or biocatalysts.[citation needed]
He is interested in the protein aggregation mechanisms,[4] and also how excipients stabilise therapeutic protein products[5] for applications in biotechnology.
Dalby has pioneered several strategies for combining rational, evolutionary and computational design tools, to engineer enzymes and therapeutic proteins with altered functions or improved stability.[6][7][8]
The current focuses of his group[9] are in the re-engineering and formulation of proteins, including viral vectors used in gene therapy.
Awards and honours
[edit]- 2023 – Royal Society of Chemistry Long Service Award
- 2010 – IChemE Bioprocessing Award[10]
- 2010 – Royal Society of Chemistry Rita and John Cornforth Award.[11]
- 2008 – Evonik European Science-to-Business Award[12]
References
[edit]- ^ "Professor Paul Dalby - People in Biochemical Engineering". profiles.ucl.ac.uk/. Retrieved 2024-04-09.
- ^ a b "Future Targeted Healthcare Manufacturing Hub". 20 September 2018. Retrieved 2024-04-09.
- ^ "Biochemical Engineering". Biochemical Engineering. 13 July 2018. Retrieved 2024-04-09.
- ^ Codina, N.; Hilton, D.; Zhang, C.; Chakroun, N.; Ahmad, S.S.; Perkins, S.J.; Dalby, P.A. (2019). "An expanded conformation of an antibody Fab region by X-ray scattering, molecular dynamics and smFRET identifies an aggregation mechanism". Journal of Molecular Biology. 431 (7): 1409–1425. doi:10.1016/j.jmb.2019.02.009. PMID 30776431.
- ^ Zhang, C.; Berg, A.; Joe, C.C.D.; Dalby, P.A.; Douglas, A.D. (2023). "Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration". npj Vaccines. 8 (1): 85. doi:10.1038/S41541-023-00674-2. PMC 10240132. PMID 37277337.
- ^ Yu, H.; Dalby, P.A. (2018). "Exploiting correlated molecular-dynamics networks to counteract enzyme activity-stability trade-off". Proceedings of the National Academy of Sciences, USA. 115 (52): E12192–E12200. Bibcode:2018PNAS..11512192Y. doi:10.1073/pnas.1812204115. PMC 6310800. PMID 30530661.
- ^ Strafford, J.; et al. (2012). "Directed evolution to re-adapt a co-evolved network within an enzyme". Journal of Biotechnology. 157 (1): 237–245. doi:10.1016/j.jbiotec.2011.11.017. PMC 3657141. PMID 22154561.
- ^ Zhang, C.; Samad, M.; Yu, H.; Chakroun, N.; Hilton, D.; Dalby, P.A. (2018). "Computational-design to reduce conformational flexibility and aggregation rates of an antibody Fab fragment". Molecular Pharmaceutics. 15 (8): 3079–3092. doi:10.1021/acs.molpharmaceut.8b00186. PMID 29897777.
- ^ "Dalby profile". Dalby profile. Retrieved 2024-04-09.
- ^ "IChemE past awards". www.icheme.org. Retrieved 2024-04-09.
- ^ "Royal Society of Chemistry Rita and John Cornforth Award". rsc.org. Retrieved 2024-04-09.
- ^ "Candidates Nominated for Evonik European Research Award". corporate.evonik.com. Retrieved 2024-04-09.